Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Aug 10, 2026

On August 10, 2026, Sionna Therapeutics announced it will halt development of its experimental cystic fibrosis drug, SION-719, after it failed to show benefit as an add-on to Vertex's Trikafta in a Phase 2 trial. The drug failed to significantly lower sweat chloride levels in 15 adult patients. Following the news, Sionna's stock plummeted up to 92% in pre-market trading, prompting the company to plan capital preservation measures, including potential layoffs, while reviewing its pipeline.

SION-719 trial failure

▪The Phase 2 clinical trial of SION-719 tested the drug as an add-on to Vertex Pharmaceuticals' Trikafta in 15 adults with cystic fibrosis.
▪Sionna Therapeutics announced on August 10, 2026, that it will stop developing its experimental drug SION-719 as an add-on therapy for cystic fibrosis.
▪SION-719 was generally well tolerated during a 14-day Phase 2 study, with mostly mild to moderate side effects and no serious side effects reported.

Sweat chloride outcome measure

▪Sionna Therapeutics stated that variations in patient test results and differences in Trikafta levels may have influenced the SION-719 trial outcome.
▪Sionna Therapeutics' stock fell between 90% and 92% in pre-market trading on August 10, 2026, following the SION-719 trial failure announcement.

Capital preservation strategy

▪Sionna Therapeutics is separately developing a two-drug cystic fibrosis treatment combining the experimental compounds SION-451 and SION-2222.
▪Sionna Therapeutics CEO Mike Cloonan expressed disappointment in the unexpected SION-719 trial results and stated the company is reviewing the data before deciding its next steps.
▪Sionna Therapeutics announced on August 10, 2026, that it will take actions to preserve capital, hinting at potential layoffs, while evaluating its next steps.